Teva Pharmaceutical Industries Limited (TEVA) 10-Year Financial Performance & Capital Metrics

TEVA • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsStandard Generics

AboutTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.Show more

Revenue $16.54B +4.4%
EBITDA $756M -52.3%
Net Income -$1.64B -193.2%
EPS (Diluted) -1.45 -190.0%
Gross Margin 48.74% +1.0%
EBITDA Margin 4.57% -54.3%
Operating Margin -1.83% -167.0%
Net Margin -9.91% -180.8%
ROE -23.67% -254.1%
ROIC -1% -180.5%
Debt/Equity 3.16 +27.4%
Interest Coverage -0.32 -176.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 91 (top 9%)
✓Trading near 52-week high

✗Weaknesses

✗High debt to equity ratio of 3.2x

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-2.01%

5Y-0.41%

3Y1.38%

TTM0.03%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM174.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM170.59%

ROCE

10Y Avg-2.94%

5Y Avg-2.04%

3Y Avg-2.01%

Latest-1.05%

Peer Comparison

Standard Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDYDr. Reddy's Laboratories Limited	10.9B	13.09	0.19	16.61%	17.13%	16.19%	100%	0.14
CPHIChina Pharma Holdings, Inc.	6.38M	1.27	-4.70	-35.41%	-86.15%	-76699.41%		0.46
TEVATeva Pharmaceutical Industries Limited	37.11B	32.35	-22.31	4.41%	4.24%	9.82%	5.52%	3.16
VTRSViatris Inc.	14.79B	12.84	-24.23	-4.46%	-26.13%	-24.26%	13.37%	0.77

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	19.65B	21.9B	22.39B	18.85B	16.89B	16.66B	15.88B	14.93B	15.85B	16.54B
Revenue Growth %	-0.03%	0.11%	0.02%	-0.16%	-0.1%	-0.01%	-0.05%	-0.06%	0.06%	0.04%
Cost of Goods Sold+	8.3B	10.04B	11.56B	10.56B	9.35B	8.93B	8.28B	7.95B	8.2B	8.48B
COGS % of Revenue	0.42%	0.46%	0.52%	0.56%	0.55%	0.54%	0.52%	0.53%	0.52%	0.51%
Gross Profit+	11.36B	11.86B	10.82B	8.3B	7.54B	7.73B	7.59B	6.97B	7.64B	8.06B
Gross Margin %	0.58%	0.54%	0.48%	0.44%	0.45%	0.46%	0.48%	0.47%	0.48%	0.49%
Gross Profit Growth %	0.03%	0.04%	-0.09%	-0.23%	-0.09%	0.03%	-0.02%	-0.08%	0.1%	0.05%
Operating Expenses+	6.24B	7.21B	6.83B	5.43B	7.98B	11.3B	5.88B	9.17B	7.21B	8.37B
OpEx % of Revenue	0.32%	0.33%	0.31%	0.29%	0.47%	0.68%	0.37%	0.61%	0.46%	0.51%
Selling, General & Admin	4.72B	5.1B	4.99B	4.21B	3.81B	3.67B	3.53B	3.44B	3.5B	3.7B
SG&A % of Revenue	0.24%	0.23%	0.22%	0.22%	0.23%	0.22%	0.22%	0.23%	0.22%	0.22%
Research & Development	1.52B	2.11B	1.85B	1.21B	1.01B	1.79B	1.09B	838M	953M	1.05B
R&D % of Revenue	0.08%	0.1%	0.08%	0.06%	0.06%	0.11%	0.07%	0.06%	0.06%	0.06%
Other Operating Expenses	23M	0	0	0	3.16B	5.83B	1.26B	4.89B	2.76B	3.61B
Operating Income+	3.35B	2.15B	-17.48B	-1.64B	-443M	-3.57B	1.72B	-2.2B	433M	-303M
Operating Margin %	0.17%	0.1%	-0.78%	-0.09%	-0.03%	-0.21%	0.11%	-0.15%	0.03%	-0.02%
Operating Income Growth %	-0.15%	-0.36%	-9.12%	0.91%	0.73%	-7.06%	1.48%	-2.28%	1.2%	-1.7%
EBITDA+	4.66B	3.65B	-15.41B	205M	1.28B	-2.02B	3.05B	-889M	1.59B	756M
EBITDA Margin %	0.24%	0.17%	-0.69%	0.01%	0.08%	-0.12%	0.19%	-0.06%	0.1%	0.05%
EBITDA Growth %	-0.15%	-0.22%	-5.22%	1.01%	5.24%	-2.58%	2.51%	-1.29%	2.78%	-0.52%
D&A (Non-Cash Add-back)	1.31B	1.49B	2.08B	1.84B	1.72B	1.56B	1.33B	1.31B	1.15B	1.06B
EBIT	2.62B	1.37B	-17.59B	-1.66B	2.72B	3.06B	3.08B	-2.23B	405M	3.37B
Net Interest Income+	-431M	-548M	-872M	-881M	-916M	-731M	-891M	-930M	-961M	-941M
Interest Income	34M	0	3M	0	41M	24M	0	0	68M	0
Interest Expense	465M	1.33B	895M	881M	957M	755M	891M	930M	1.03B	941M
Other Income/Expense	-1B	-1.33B	-895M	-959M	-280M	-359M	-1.05B	-945M	-1.05B	-980M
Pretax Income+	2.35B	824M	-18.38B	-2.6B	-723M	-3.93B	667M	-3.14B	-622M	-1.28B
Pretax Margin %	0.12%	0.04%	-0.82%	-0.14%	-0.04%	-0.24%	0.04%	-0.21%	-0.04%	-0.08%
Income Tax+	634M	521M	-1.93B	-195M	278M	168M	211M	-643M	-7M	676M
Effective Tax Rate %	0.68%	0.4%	0.88%	0.83%	1.38%	1.02%	0.63%	0.78%	0.9%	1.28%
Net Income+	1.59B	329M	-16.27B	-2.15B	-999M	-3.99B	417M	-2.45B	-559M	-1.64B
Net Margin %	0.08%	0.02%	-0.73%	-0.11%	-0.06%	-0.24%	0.03%	-0.16%	-0.04%	-0.1%
Net Income Growth %	-0.48%	-0.79%	-50.44%	0.87%	0.54%	-2.99%	1.1%	-6.87%	0.77%	-1.93%
Net Income (Continuing)	1.6B	311M	-16.45B	-2.47B	-1B	-4.1B	456M	-2.5B	-615M	-1.96B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	158M	1.66B	1.39B	1.09B	1.09B	1.03B	966M	794M	620M	347M
EPS (Diluted)+	1.82	0.07	-16.01	-2.11	-0.92	-3.64	0.38	-2.20	-0.50	-1.45
EPS Growth %	-0.49%	-0.96%	-229.71%	0.87%	0.56%	-2.96%	1.1%	-6.79%	0.77%	-1.9%
EPS (Basic)	1.84	0.07	-16.01	-2.11	-0.92	-3.64	0.38	-2.20	-0.50	-1.45
Diluted Shares Outstanding	864M	961M	1.02B	1.02B	1.09B	1.09B	1.11B	1.11B	1.12B	1.13B
Basic Shares Outstanding	855M	955M	1.02B	1.02B	1.09B	1.09B	1.1B	1.11B	1.12B	1.13B
Dividend Payout Ratio	0.73%	3.96%	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	18.4B	16.96B	15.38B	13.79B	13.46B	13.01B	12.57B	12.05B	12.48B	12.55B
Cash & Short-Term Investments	6.95B	988M	963M	1.78B	1.98B	2.18B	2.17B	2.8B	3.23B	3.3B
Cash Only	6.95B	988M	963M	1.78B	1.98B	2.18B	2.17B	2.8B	3.23B	3.3B
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	5.35B	7.52B	7.13B	5.82B	5.68B	4.58B	4.53B	3.7B	3.41B	3.06B
Days Sales Outstanding	99.37	125.37	116.23	112.71	122.68	100.37	104.11	90.39	78.51	67.49
Inventory	3.97B	4.95B	4.92B	4.73B	4.42B	4.4B	3.82B	3.83B	4.02B	3.01B
Days Inventory Outstanding	174.49	180.03	155.47	163.56	172.61	179.91	168.22	175.94	178.98	129.41
Other Current Assets	1.23B	2.13B	1.27B	560M	521M	899M	986M	559M	575M	2.18B
Total Non-Current Assets+	35.86B	75.93B	55.23B	46.89B	44.01B	37.63B	35.09B	31.96B	30.99B	26.77B
Property, Plant & Equipment	6.54B	8.07B	7.67B	6.87B	6.95B	6.85B	6.48B	6.16B	6.15B	4.95B
Fixed Asset Turnover	3.00x	2.71x	2.92x	2.75x	2.43x	2.43x	2.45x	2.42x	2.58x	3.34x
Goodwill	19.02B	44.41B	28.41B	24.92B	24.85B	20.62B	20.04B	17.63B	17.18B	15.15B
Intangible Assets	7.67B	21.49B	17.64B	14.01B	11.23B	8.92B	7.47B	6.27B	5.39B	4.42B
Long-Term Investments	1.45B	88M	25M	58M	0	0	0	0	0	0
Other Non-Current Assets	2.62B	1.15B	907M	673M	591M	538M	515M	441M	470M	462M
Total Assets+	54.26B	92.89B	70.61B	60.68B	57.47B	50.64B	47.67B	44.01B	43.48B	39.33B
Asset Turnover	0.36x	0.24x	0.32x	0.31x	0.29x	0.33x	0.33x	0.34x	0.36x	0.42x
Asset Growth %	0.17%	0.71%	-0.24%	-0.14%	-0.05%	-0.12%	-0.06%	-0.08%	-0.01%	-0.1%
Total Current Liabilities+	13.01B	18.52B	17.92B	14.32B	13.67B	13.16B	11.03B	11.47B	12.25B	12.8B
Accounts Payable	1.92B	2.16B	2.07B	1.85B	1.72B	1.76B	1.69B	1.89B	2.6B	2.2B
Days Payables Outstanding	84.39	78.39	65.33	64.06	67.06	71.75	74.29	86.61	115.82	94.81
Short-Term Debt	1.58B	3.28B	3.65B	2.22B	2.35B	3.19B	1.43B	2.11B	1.67B	1.78B
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	1000K	0	0	0	0
Other Current Liabilities	7.82B	12.2B	11.66B	9.38B	7.74B	246M	5.71B	5.32B	5.2B	6.02B
Current Ratio	1.41x	0.92x	0.86x	0.96x	0.98x	0.99x	1.14x	1.05x	1.02x	0.98x
Quick Ratio	1.11x	0.65x	0.58x	0.63x	0.66x	0.65x	0.79x	0.72x	0.69x	0.75x
Cash Conversion Cycle	189.47	227.01	206.37	212.2	228.23	208.53	198.05	179.71	141.67	102.09
Total Non-Current Liabilities+	11.33B	39.38B	33.95B	30.57B	28.73B	26.41B	25.39B	23.94B	23.11B	20.81B
Long-Term Debt	8.38B	32.52B	28.83B	26.7B	24.56B	22.73B	21.62B	19.1B	18.16B	16B
Capital Lease Obligations	0	0	0	0	435M	479M	416M	349M	320M	296M
Deferred Tax Liabilities	1.75B	5.21B	3.28B	2.14B	1.1B	964M	784M	548M	606M	483M
Other Non-Current Liabilities	1.2B	1.64B	1.84B	1.73B	2.64B	2.24B	2.58B	3.94B	4.02B	4.03B
Total Liabilities	24.33B	57.9B	51.87B	44.89B	42.41B	39.58B	36.42B	35.41B	35.35B	33.61B
Total Debt+	9.97B	35.8B	32.48B	28.92B	27.34B	26.4B	23.46B	21.56B	20.15B	18.08B
Net Debt	3.02B	34.81B	31.51B	27.13B	25.37B	24.22B	21.29B	18.76B	16.93B	14.78B
Debt / Equity	0.33x	1.02x	1.73x	1.83x	1.82x	2.39x	2.09x	2.51x	2.48x	3.16x
Debt / EBITDA	2.14x	9.81x	-	141.05x	21.38x	-	7.70x	-	12.71x	23.91x
Net Debt / EBITDA	0.65x	9.54x	-	132.36x	19.83x	-	6.99x	-	10.67x	19.55x
Interest Coverage	7.21x	1.62x	-19.54x	-1.86x	-0.46x	-4.73x	1.93x	-2.36x	0.42x	-0.32x
Total Equity+	29.93B	34.99B	18.75B	15.79B	15.06B	11.06B	11.24B	8.6B	8.13B	5.72B
Equity Growth %	0.28%	0.17%	-0.46%	-0.16%	-0.05%	-0.27%	0.02%	-0.24%	-0.05%	-0.3%
Book Value per Share	34.64	36.41	18.45	15.47	13.81	10.10	10.16	7.75	7.26	5.06
Total Shareholders' Equity	29.77B	33.34B	17.36B	14.71B	13.97B	10.03B	10.28B	7.8B	7.51B	5.37B
Common Stock	52M	54M	54M	56M	56M	57M	57M	57M	57M	58M
Retained Earnings	14.85B	13.61B	-3.8B	-5.96B	-6.96B	-10.95B	-10.53B	-12.97B	-13.53B	-15.17B
Treasury Stock	-4.23B	-4.19B	-4.15B	-4.14B	-4.13B	-4.13B	-4.13B	-4.13B	-4.13B	-4.13B
Accumulated OCI	-1.96B	-3.16B	-1.85B	-2.46B	-2.31B	-2.4B	-2.68B	-2.84B	-2.7B	-3.15B
Minority Interest	158M	1.66B	1.39B	1.09B	1.09B	1.03B	966M	794M	620M	347M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	5.54B	5.22B	3.51B	2.45B	538M	1.22B	798M	1.59B	1.37B	2.55B
Operating CF Margin %	0.28%	0.24%	0.16%	0.13%	0.03%	0.07%	0.05%	0.11%	0.09%	0.15%
Operating CF Growth %	0.08%	-0.06%	-0.33%	-0.3%	-0.78%	1.26%	-0.34%	0.99%	-0.14%	0.86%
Net Income	1.6B	311M	-16.45B	-2.47B	76M	-4.1B	456M	-2.41B	-615M	-1.65B
Depreciation & Amortization	1.31B	1.52B	2.11B	1.84B	416M	1.56B	1.33B	1.31B	1.15B	1.06B
Stock-Based Compensation	117M	124M	133M	155M	20M	129M	119M	124M	121M	0
Deferred Taxes	237M	15M	-2.33B	-837M	-333M	-696M	-120M	-1.06B	-317M	-637.01M
Other Non-Cash Items	1.32B	2.03B	20.41B	5.58B	471M	6.51B	714M	2.37B	1.1B	4.21B
Working Capital Changes	967M	1.22B	-363M	-1.82B	-112M	-2.19B	-1.7B	1.26B	-72M	-437.06M
Change in Receivables	763M	343M	514M	88M	-394M	-293M	-574M	334M	12M	0
Change in Inventory	129M	753M	266M	26M	271M	41M	380M	-163M	-147M	0
Change in Payables	-12M	640M	-1.8B	-500M	643M	-463M	764M	1.91B	1.59B	0
Cash from Investing+	-5.57B	-35.74B	2.16B	1.87B	430M	863M	1.52B	656M	968M	-565.67M
Capital Expenditures	-772M	-901M	-874M	-651M	-119M	-578M	-562M	-548M	-526M	-500.36M
CapEx % of Revenue	0.04%	0.04%	0.04%	0.03%	0.01%	0.03%	0.04%	0.04%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	519M	1.79B	3.19B	11M	552M	1.42B	1M	1.14B	1.47B	-26.12M
Cash from Financing+	4.8B	25.22B	-5.75B	-3.35B	-241M	-1.89B	-2.17B	-1.49B	-1.91B	-1.74B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.16B	-1.56B	-1.16B	-22M	-52M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	6.79B	-134M	-112M	-57M	1.67B	-5M	-6M	-118M	-212M	-86.41M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.77B	4.32B	2.63B	1.79B	419M	638M	236M	1.04B	842M	2.05B
FCF Margin %	0.24%	0.2%	0.12%	0.1%	0.02%	0.04%	0.01%	0.07%	0.05%	0.12%
FCF Growth %	0.14%	-0.09%	-0.39%	-0.32%	-0.77%	0.52%	-0.63%	3.42%	-0.19%	1.43%
FCF per Share	5.52	4.50	2.59	1.76	0.38	0.58	0.21	0.94	0.75	1.81
FCF Conversion (FCF/Net Income)	3.49x	15.88x	-0.22x	-1.14x	-0.54x	-0.30x	1.91x	-0.65x	-2.45x	-1.56x
Interest Paid	243M	290M	795M	815M	840M	846M	913M	948M	1.08B	0
Taxes Paid	802M	341M	106M	420M	552M	709M	495M	543M	298M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	5.96%	1.01%	-60.53%	-12.45%	-6.48%	-30.55%	3.74%	-24.65%	-6.69%	-23.67%
Return on Invested Capital (ROIC)	7.81%	3.14%	-21.84%	-2.64%	-0.8%	-7.08%	3.8%	-5.5%	1.24%	-1%
Gross Margin	57.79%	54.14%	48.36%	44%	44.63%	46.38%	47.83%	46.72%	48.25%	48.74%
Net Margin	8.08%	1.5%	-72.66%	-11.4%	-5.92%	-23.95%	2.63%	-16.39%	-3.53%	-9.91%
Debt / Equity	0.33x	1.02x	1.73x	1.83x	1.82x	2.39x	2.09x	2.51x	2.48x	3.16x
Interest Coverage	7.21x	1.62x	-19.54x	-1.86x	-0.46x	-4.73x	1.93x	-2.36x	0.42x	-0.32x
FCF Conversion	3.49x	15.88x	-0.22x	-1.14x	-0.54x	-0.30x	1.91x	-0.65x	-2.45x	-1.56x
Revenue Growth	-3.06%	11.45%	2.2%	-15.77%	-10.43%	-1.35%	-4.69%	-6%	6.16%	4.41%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	14.35B	13.83B	12.77B	12.98B	14.43B
Product Growth	-	-	-	-	-	-	-3.66%	-7.69%	1.67%	11.18%
Distribution Service	-	-	-	-	-	1.5B	1.39B	1.52B	1.61B	1.58B
Distribution Service Growth	-	-	-	-	-	-	-7.02%	9.28%	6.32%	-2.41%
Product and Service, Other	-	-	-	-	-	680M	500M	428M	570M	365M
Product and Service, Other Growth	-	-	-	-	-	-	-26.47%	-14.40%	33.18%	-35.96%
License	-	-	-	-	-	129M	160M	212M	681M	173M
License Growth	-	-	-	-	-	-	24.03%	32.50%	221.23%	-74.60%
International Markets	-	-	-	3B	2.25B	-	-	-	-	-
International Markets Growth	-	-	-	-	-25.26%	-	-	-	-	-
Other Activities	-	-	-	1.37B	1.3B	-	-	-	-	-
Other Activities Growth	-	-	-	-	-4.54%	-	-	-	-	-
Branded	8.34B	8.67B	7.91B	-	-	-	-	-	-	-
Branded Growth	-	4.03%	-8.76%	-	-	-	-	-	-	-
Branded CNS	5.21B	5.28B	4.43B	-	-	-	-	-	-	-
Branded CNS Growth	-	1.34%	-16.22%	-	-	-	-	-	-	-
Branded C N S Copaxone	4.02B	4.22B	3.8B	-	-	-	-	-	-	-
Branded C N S Copaxone Growth	-	4.97%	-9.99%	-	-	-	-	-	-	-
Branded Respiratory Products	1.13B	1.27B	1.27B	-	-	-	-	-	-	-
Branded Respiratory Products Growth	-	12.84%	-0.31%	-	-	-	-	-	-	-
Branded Oncology Products	1.2B	1.14B	1.14B	-	-	-	-	-	-	-
Branded Oncology Products Growth	-	-5.16%	-0.35%	-	-	-	-	-	-	-
Branded Oncology Treanda and Bendeka	-	661M	658M	-	-	-	-	-	-	-
Branded Oncology Treanda and Bendeka Growth	-	-	-0.45%	-	-	-	-	-	-	-
Other Branded Products	334M	520M	657M	-	-	-	-	-	-	-
Other Branded Products Growth	-	55.69%	26.35%	-	-	-	-	-	-	-
Branded Respiratory Proair	549M	565M	501M	-	-	-	-	-	-	-
Branded Respiratory Proair Growth	-	2.91%	-11.33%	-	-	-	-	-	-	-
Branded Womens Health Products	461M	458M	426M	-	-	-	-	-	-	-
Branded Womens Health Products Growth	-	-0.65%	-6.99%	-	-	-	-	-	-	-
Branded Respiratory Qvar	392M	462M	361M	-	-	-	-	-	-	-
Branded Respiratory Qvar Growth	-	17.86%	-21.86%	-	-	-	-	-	-	-
Branded C N S Azilect	384M	410M	170M	-	-	-	-	-	-	-
Branded C N S Azilect Growth	-	6.77%	-58.54%	-	-	-	-	-	-	-
Ninlaro1	-	-	150M	-	-	-	-	-	-	-
Ninlaro1 Growth	-	-	-	-	-	-	-	-	-	-
Branded C N S Nuvigil	373M	200M	61M	-	-	-	-	-	-	-
Branded C N S Nuvigil Growth	-	-46.38%	-69.50%	-	-	-	-	-	-	-
Branded Oncology Treanda	741M	-	-	-	-	-	-	-	-	-
Branded Oncology Treanda Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	-	-	8.45B	7.81B	7.45B	8.12B	8.03B
North America Growth	-	-	-	-	-	-	-7.55%	-4.57%	9.02%	-1.11%
Europe	-	-	-	-	-	4.76B	4.89B	4.53B	4.84B	5.1B
Europe Growth	-	-	-	-	-	-	2.71%	-7.39%	6.90%	5.50%
International Markets	-	-	-	-	-	2.15B	2.03B	1.9B	1.96B	2.46B
International Markets Growth	-	-	-	-	-	-	-5.66%	-6.35%	2.89%	25.79%
North America	-	-	-	7.84B	6.94B	-	-	-	-	-
North America Growth	-	-	-	-	-11.44%	-	-	-	-	-
Europe	-	-	-	5.15B	4.77B	-	-	-	-	-
Europe Growth	-	-	-	-	-7.43%	-	-	-	-	-
Rest Of The World	3.51B	4.84B	655M	-	-	-	-	-	-	-
Rest Of The World Growth	-	37.92%	-86.48%	-	-	-	-	-	-	-
Europe Group Two	4.89B	5.41B	308M	-	-	-	-	-	-	-
Europe Group Two Growth	-	10.61%	-94.31%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Teva Pharmaceutical Industries Limited (TEVA) reported $16.78B in revenue for fiscal year 2024. This represents a 8% decrease from $18.31B in 2011.

Teva Pharmaceutical Industries Limited (TEVA) grew revenue by 4.4% over the past year. Growth has been modest.

Yes, Teva Pharmaceutical Industries Limited (TEVA) is profitable, generating $712.0M in net income for fiscal year 2024 (-9.9% net margin).

Dividend & Returns

Teva Pharmaceutical Industries Limited (TEVA) has a return on equity (ROE) of -23.7%. Negative ROE indicates the company is unprofitable.

Teva Pharmaceutical Industries Limited (TEVA) generated $918.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Teva Pharmaceutical Industries Limited (TEVA) 10-Year Financial Performance & Capital Metrics

TEVA • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsStandard Generics

Revenue $16.54B +4.4%
EBITDA $756M -52.3%
Net Income -$1.64B -193.2%
EPS (Diluted) -1.45 -190.0%
Gross Margin 48.74% +1.0%
EBITDA Margin 4.57% -54.3%
Operating Margin -1.83% -167.0%
Net Margin -9.91% -180.8%
ROE -23.67% -254.1%
ROIC -1% -180.5%
Debt/Equity 3.16 +27.4%
Interest Coverage -0.32 -176.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 91 (top 9%)
✓Trading near 52-week high

✗Weaknesses

✗High debt to equity ratio of 3.2x

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-2.01%

5Y-0.41%

3Y1.38%

TTM0.03%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM174.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM170.59%

ROCE

10Y Avg-2.94%

5Y Avg-2.04%

3Y Avg-2.01%

Latest-1.05%

Peer Comparison

Standard Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDYDr. Reddy's Laboratories Limited	10.9B	13.09	0.19	16.61%	17.13%	16.19%	100%	0.14
CPHIChina Pharma Holdings, Inc.	6.38M	1.27	-4.70	-35.41%	-86.15%	-76699.41%		0.46
TEVATeva Pharmaceutical Industries Limited	37.11B	32.35	-22.31	4.41%	4.24%	9.82%	5.52%	3.16
VTRSViatris Inc.	14.79B	12.84	-24.23	-4.46%	-26.13%	-24.26%	13.37%	0.77

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	19.65B	21.9B	22.39B	18.85B	16.89B	16.66B	15.88B	14.93B	15.85B	16.54B
Revenue Growth %	-0.03%	0.11%	0.02%	-0.16%	-0.1%	-0.01%	-0.05%	-0.06%	0.06%	0.04%
Cost of Goods Sold+	8.3B	10.04B	11.56B	10.56B	9.35B	8.93B	8.28B	7.95B	8.2B	8.48B
COGS % of Revenue	0.42%	0.46%	0.52%	0.56%	0.55%	0.54%	0.52%	0.53%	0.52%	0.51%
Gross Profit+	11.36B	11.86B	10.82B	8.3B	7.54B	7.73B	7.59B	6.97B	7.64B	8.06B
Gross Margin %	0.58%	0.54%	0.48%	0.44%	0.45%	0.46%	0.48%	0.47%	0.48%	0.49%
Gross Profit Growth %	0.03%	0.04%	-0.09%	-0.23%	-0.09%	0.03%	-0.02%	-0.08%	0.1%	0.05%
Operating Expenses+	6.24B	7.21B	6.83B	5.43B	7.98B	11.3B	5.88B	9.17B	7.21B	8.37B
OpEx % of Revenue	0.32%	0.33%	0.31%	0.29%	0.47%	0.68%	0.37%	0.61%	0.46%	0.51%
Selling, General & Admin	4.72B	5.1B	4.99B	4.21B	3.81B	3.67B	3.53B	3.44B	3.5B	3.7B
SG&A % of Revenue	0.24%	0.23%	0.22%	0.22%	0.23%	0.22%	0.22%	0.23%	0.22%	0.22%
Research & Development	1.52B	2.11B	1.85B	1.21B	1.01B	1.79B	1.09B	838M	953M	1.05B
R&D % of Revenue	0.08%	0.1%	0.08%	0.06%	0.06%	0.11%	0.07%	0.06%	0.06%	0.06%
Other Operating Expenses	23M	0	0	0	3.16B	5.83B	1.26B	4.89B	2.76B	3.61B
Operating Income+	3.35B	2.15B	-17.48B	-1.64B	-443M	-3.57B	1.72B	-2.2B	433M	-303M
Operating Margin %	0.17%	0.1%	-0.78%	-0.09%	-0.03%	-0.21%	0.11%	-0.15%	0.03%	-0.02%
Operating Income Growth %	-0.15%	-0.36%	-9.12%	0.91%	0.73%	-7.06%	1.48%	-2.28%	1.2%	-1.7%
EBITDA+	4.66B	3.65B	-15.41B	205M	1.28B	-2.02B	3.05B	-889M	1.59B	756M
EBITDA Margin %	0.24%	0.17%	-0.69%	0.01%	0.08%	-0.12%	0.19%	-0.06%	0.1%	0.05%
EBITDA Growth %	-0.15%	-0.22%	-5.22%	1.01%	5.24%	-2.58%	2.51%	-1.29%	2.78%	-0.52%
D&A (Non-Cash Add-back)	1.31B	1.49B	2.08B	1.84B	1.72B	1.56B	1.33B	1.31B	1.15B	1.06B
EBIT	2.62B	1.37B	-17.59B	-1.66B	2.72B	3.06B	3.08B	-2.23B	405M	3.37B
Net Interest Income+	-431M	-548M	-872M	-881M	-916M	-731M	-891M	-930M	-961M	-941M
Interest Income	34M	0	3M	0	41M	24M	0	0	68M	0
Interest Expense	465M	1.33B	895M	881M	957M	755M	891M	930M	1.03B	941M
Other Income/Expense	-1B	-1.33B	-895M	-959M	-280M	-359M	-1.05B	-945M	-1.05B	-980M
Pretax Income+	2.35B	824M	-18.38B	-2.6B	-723M	-3.93B	667M	-3.14B	-622M	-1.28B
Pretax Margin %	0.12%	0.04%	-0.82%	-0.14%	-0.04%	-0.24%	0.04%	-0.21%	-0.04%	-0.08%
Income Tax+	634M	521M	-1.93B	-195M	278M	168M	211M	-643M	-7M	676M
Effective Tax Rate %	0.68%	0.4%	0.88%	0.83%	1.38%	1.02%	0.63%	0.78%	0.9%	1.28%
Net Income+	1.59B	329M	-16.27B	-2.15B	-999M	-3.99B	417M	-2.45B	-559M	-1.64B
Net Margin %	0.08%	0.02%	-0.73%	-0.11%	-0.06%	-0.24%	0.03%	-0.16%	-0.04%	-0.1%
Net Income Growth %	-0.48%	-0.79%	-50.44%	0.87%	0.54%	-2.99%	1.1%	-6.87%	0.77%	-1.93%
Net Income (Continuing)	1.6B	311M	-16.45B	-2.47B	-1B	-4.1B	456M	-2.5B	-615M	-1.96B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	158M	1.66B	1.39B	1.09B	1.09B	1.03B	966M	794M	620M	347M
EPS (Diluted)+	1.82	0.07	-16.01	-2.11	-0.92	-3.64	0.38	-2.20	-0.50	-1.45
EPS Growth %	-0.49%	-0.96%	-229.71%	0.87%	0.56%	-2.96%	1.1%	-6.79%	0.77%	-1.9%
EPS (Basic)	1.84	0.07	-16.01	-2.11	-0.92	-3.64	0.38	-2.20	-0.50	-1.45
Diluted Shares Outstanding	864M	961M	1.02B	1.02B	1.09B	1.09B	1.11B	1.11B	1.12B	1.13B
Basic Shares Outstanding	855M	955M	1.02B	1.02B	1.09B	1.09B	1.1B	1.11B	1.12B	1.13B
Dividend Payout Ratio	0.73%	3.96%	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	18.4B	16.96B	15.38B	13.79B	13.46B	13.01B	12.57B	12.05B	12.48B	12.55B
Cash & Short-Term Investments	6.95B	988M	963M	1.78B	1.98B	2.18B	2.17B	2.8B	3.23B	3.3B
Cash Only	6.95B	988M	963M	1.78B	1.98B	2.18B	2.17B	2.8B	3.23B	3.3B
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	5.35B	7.52B	7.13B	5.82B	5.68B	4.58B	4.53B	3.7B	3.41B	3.06B
Days Sales Outstanding	99.37	125.37	116.23	112.71	122.68	100.37	104.11	90.39	78.51	67.49
Inventory	3.97B	4.95B	4.92B	4.73B	4.42B	4.4B	3.82B	3.83B	4.02B	3.01B
Days Inventory Outstanding	174.49	180.03	155.47	163.56	172.61	179.91	168.22	175.94	178.98	129.41
Other Current Assets	1.23B	2.13B	1.27B	560M	521M	899M	986M	559M	575M	2.18B
Total Non-Current Assets+	35.86B	75.93B	55.23B	46.89B	44.01B	37.63B	35.09B	31.96B	30.99B	26.77B
Property, Plant & Equipment	6.54B	8.07B	7.67B	6.87B	6.95B	6.85B	6.48B	6.16B	6.15B	4.95B
Fixed Asset Turnover	3.00x	2.71x	2.92x	2.75x	2.43x	2.43x	2.45x	2.42x	2.58x	3.34x
Goodwill	19.02B	44.41B	28.41B	24.92B	24.85B	20.62B	20.04B	17.63B	17.18B	15.15B
Intangible Assets	7.67B	21.49B	17.64B	14.01B	11.23B	8.92B	7.47B	6.27B	5.39B	4.42B
Long-Term Investments	1.45B	88M	25M	58M	0	0	0	0	0	0
Other Non-Current Assets	2.62B	1.15B	907M	673M	591M	538M	515M	441M	470M	462M
Total Assets+	54.26B	92.89B	70.61B	60.68B	57.47B	50.64B	47.67B	44.01B	43.48B	39.33B
Asset Turnover	0.36x	0.24x	0.32x	0.31x	0.29x	0.33x	0.33x	0.34x	0.36x	0.42x
Asset Growth %	0.17%	0.71%	-0.24%	-0.14%	-0.05%	-0.12%	-0.06%	-0.08%	-0.01%	-0.1%
Total Current Liabilities+	13.01B	18.52B	17.92B	14.32B	13.67B	13.16B	11.03B	11.47B	12.25B	12.8B
Accounts Payable	1.92B	2.16B	2.07B	1.85B	1.72B	1.76B	1.69B	1.89B	2.6B	2.2B
Days Payables Outstanding	84.39	78.39	65.33	64.06	67.06	71.75	74.29	86.61	115.82	94.81
Short-Term Debt	1.58B	3.28B	3.65B	2.22B	2.35B	3.19B	1.43B	2.11B	1.67B	1.78B
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	1000K	0	0	0	0
Other Current Liabilities	7.82B	12.2B	11.66B	9.38B	7.74B	246M	5.71B	5.32B	5.2B	6.02B
Current Ratio	1.41x	0.92x	0.86x	0.96x	0.98x	0.99x	1.14x	1.05x	1.02x	0.98x
Quick Ratio	1.11x	0.65x	0.58x	0.63x	0.66x	0.65x	0.79x	0.72x	0.69x	0.75x
Cash Conversion Cycle	189.47	227.01	206.37	212.2	228.23	208.53	198.05	179.71	141.67	102.09
Total Non-Current Liabilities+	11.33B	39.38B	33.95B	30.57B	28.73B	26.41B	25.39B	23.94B	23.11B	20.81B
Long-Term Debt	8.38B	32.52B	28.83B	26.7B	24.56B	22.73B	21.62B	19.1B	18.16B	16B
Capital Lease Obligations	0	0	0	0	435M	479M	416M	349M	320M	296M
Deferred Tax Liabilities	1.75B	5.21B	3.28B	2.14B	1.1B	964M	784M	548M	606M	483M
Other Non-Current Liabilities	1.2B	1.64B	1.84B	1.73B	2.64B	2.24B	2.58B	3.94B	4.02B	4.03B
Total Liabilities	24.33B	57.9B	51.87B	44.89B	42.41B	39.58B	36.42B	35.41B	35.35B	33.61B
Total Debt+	9.97B	35.8B	32.48B	28.92B	27.34B	26.4B	23.46B	21.56B	20.15B	18.08B
Net Debt	3.02B	34.81B	31.51B	27.13B	25.37B	24.22B	21.29B	18.76B	16.93B	14.78B
Debt / Equity	0.33x	1.02x	1.73x	1.83x	1.82x	2.39x	2.09x	2.51x	2.48x	3.16x
Debt / EBITDA	2.14x	9.81x	-	141.05x	21.38x	-	7.70x	-	12.71x	23.91x
Net Debt / EBITDA	0.65x	9.54x	-	132.36x	19.83x	-	6.99x	-	10.67x	19.55x
Interest Coverage	7.21x	1.62x	-19.54x	-1.86x	-0.46x	-4.73x	1.93x	-2.36x	0.42x	-0.32x
Total Equity+	29.93B	34.99B	18.75B	15.79B	15.06B	11.06B	11.24B	8.6B	8.13B	5.72B
Equity Growth %	0.28%	0.17%	-0.46%	-0.16%	-0.05%	-0.27%	0.02%	-0.24%	-0.05%	-0.3%
Book Value per Share	34.64	36.41	18.45	15.47	13.81	10.10	10.16	7.75	7.26	5.06
Total Shareholders' Equity	29.77B	33.34B	17.36B	14.71B	13.97B	10.03B	10.28B	7.8B	7.51B	5.37B
Common Stock	52M	54M	54M	56M	56M	57M	57M	57M	57M	58M
Retained Earnings	14.85B	13.61B	-3.8B	-5.96B	-6.96B	-10.95B	-10.53B	-12.97B	-13.53B	-15.17B
Treasury Stock	-4.23B	-4.19B	-4.15B	-4.14B	-4.13B	-4.13B	-4.13B	-4.13B	-4.13B	-4.13B
Accumulated OCI	-1.96B	-3.16B	-1.85B	-2.46B	-2.31B	-2.4B	-2.68B	-2.84B	-2.7B	-3.15B
Minority Interest	158M	1.66B	1.39B	1.09B	1.09B	1.03B	966M	794M	620M	347M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	5.54B	5.22B	3.51B	2.45B	538M	1.22B	798M	1.59B	1.37B	2.55B
Operating CF Margin %	0.28%	0.24%	0.16%	0.13%	0.03%	0.07%	0.05%	0.11%	0.09%	0.15%
Operating CF Growth %	0.08%	-0.06%	-0.33%	-0.3%	-0.78%	1.26%	-0.34%	0.99%	-0.14%	0.86%
Net Income	1.6B	311M	-16.45B	-2.47B	76M	-4.1B	456M	-2.41B	-615M	-1.65B
Depreciation & Amortization	1.31B	1.52B	2.11B	1.84B	416M	1.56B	1.33B	1.31B	1.15B	1.06B
Stock-Based Compensation	117M	124M	133M	155M	20M	129M	119M	124M	121M	0
Deferred Taxes	237M	15M	-2.33B	-837M	-333M	-696M	-120M	-1.06B	-317M	-637.01M
Other Non-Cash Items	1.32B	2.03B	20.41B	5.58B	471M	6.51B	714M	2.37B	1.1B	4.21B
Working Capital Changes	967M	1.22B	-363M	-1.82B	-112M	-2.19B	-1.7B	1.26B	-72M	-437.06M
Change in Receivables	763M	343M	514M	88M	-394M	-293M	-574M	334M	12M	0
Change in Inventory	129M	753M	266M	26M	271M	41M	380M	-163M	-147M	0
Change in Payables	-12M	640M	-1.8B	-500M	643M	-463M	764M	1.91B	1.59B	0
Cash from Investing+	-5.57B	-35.74B	2.16B	1.87B	430M	863M	1.52B	656M	968M	-565.67M
Capital Expenditures	-772M	-901M	-874M	-651M	-119M	-578M	-562M	-548M	-526M	-500.36M
CapEx % of Revenue	0.04%	0.04%	0.04%	0.03%	0.01%	0.03%	0.04%	0.04%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	519M	1.79B	3.19B	11M	552M	1.42B	1M	1.14B	1.47B	-26.12M
Cash from Financing+	4.8B	25.22B	-5.75B	-3.35B	-241M	-1.89B	-2.17B	-1.49B	-1.91B	-1.74B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.16B	-1.56B	-1.16B	-22M	-52M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	6.79B	-134M	-112M	-57M	1.67B	-5M	-6M	-118M	-212M	-86.41M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.77B	4.32B	2.63B	1.79B	419M	638M	236M	1.04B	842M	2.05B
FCF Margin %	0.24%	0.2%	0.12%	0.1%	0.02%	0.04%	0.01%	0.07%	0.05%	0.12%
FCF Growth %	0.14%	-0.09%	-0.39%	-0.32%	-0.77%	0.52%	-0.63%	3.42%	-0.19%	1.43%
FCF per Share	5.52	4.50	2.59	1.76	0.38	0.58	0.21	0.94	0.75	1.81
FCF Conversion (FCF/Net Income)	3.49x	15.88x	-0.22x	-1.14x	-0.54x	-0.30x	1.91x	-0.65x	-2.45x	-1.56x
Interest Paid	243M	290M	795M	815M	840M	846M	913M	948M	1.08B	0
Taxes Paid	802M	341M	106M	420M	552M	709M	495M	543M	298M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	5.96%	1.01%	-60.53%	-12.45%	-6.48%	-30.55%	3.74%	-24.65%	-6.69%	-23.67%
Return on Invested Capital (ROIC)	7.81%	3.14%	-21.84%	-2.64%	-0.8%	-7.08%	3.8%	-5.5%	1.24%	-1%
Gross Margin	57.79%	54.14%	48.36%	44%	44.63%	46.38%	47.83%	46.72%	48.25%	48.74%
Net Margin	8.08%	1.5%	-72.66%	-11.4%	-5.92%	-23.95%	2.63%	-16.39%	-3.53%	-9.91%
Debt / Equity	0.33x	1.02x	1.73x	1.83x	1.82x	2.39x	2.09x	2.51x	2.48x	3.16x
Interest Coverage	7.21x	1.62x	-19.54x	-1.86x	-0.46x	-4.73x	1.93x	-2.36x	0.42x	-0.32x
FCF Conversion	3.49x	15.88x	-0.22x	-1.14x	-0.54x	-0.30x	1.91x	-0.65x	-2.45x	-1.56x
Revenue Growth	-3.06%	11.45%	2.2%	-15.77%	-10.43%	-1.35%	-4.69%	-6%	6.16%	4.41%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	14.35B	13.83B	12.77B	12.98B	14.43B
Product Growth	-	-	-	-	-	-	-3.66%	-7.69%	1.67%	11.18%
Distribution Service	-	-	-	-	-	1.5B	1.39B	1.52B	1.61B	1.58B
Distribution Service Growth	-	-	-	-	-	-	-7.02%	9.28%	6.32%	-2.41%
Product and Service, Other	-	-	-	-	-	680M	500M	428M	570M	365M
Product and Service, Other Growth	-	-	-	-	-	-	-26.47%	-14.40%	33.18%	-35.96%
License	-	-	-	-	-	129M	160M	212M	681M	173M
License Growth	-	-	-	-	-	-	24.03%	32.50%	221.23%	-74.60%
International Markets	-	-	-	3B	2.25B	-	-	-	-	-
International Markets Growth	-	-	-	-	-25.26%	-	-	-	-	-
Other Activities	-	-	-	1.37B	1.3B	-	-	-	-	-
Other Activities Growth	-	-	-	-	-4.54%	-	-	-	-	-
Branded	8.34B	8.67B	7.91B	-	-	-	-	-	-	-
Branded Growth	-	4.03%	-8.76%	-	-	-	-	-	-	-
Branded CNS	5.21B	5.28B	4.43B	-	-	-	-	-	-	-
Branded CNS Growth	-	1.34%	-16.22%	-	-	-	-	-	-	-
Branded C N S Copaxone	4.02B	4.22B	3.8B	-	-	-	-	-	-	-
Branded C N S Copaxone Growth	-	4.97%	-9.99%	-	-	-	-	-	-	-
Branded Respiratory Products	1.13B	1.27B	1.27B	-	-	-	-	-	-	-
Branded Respiratory Products Growth	-	12.84%	-0.31%	-	-	-	-	-	-	-
Branded Oncology Products	1.2B	1.14B	1.14B	-	-	-	-	-	-	-
Branded Oncology Products Growth	-	-5.16%	-0.35%	-	-	-	-	-	-	-
Branded Oncology Treanda and Bendeka	-	661M	658M	-	-	-	-	-	-	-
Branded Oncology Treanda and Bendeka Growth	-	-	-0.45%	-	-	-	-	-	-	-
Other Branded Products	334M	520M	657M	-	-	-	-	-	-	-
Other Branded Products Growth	-	55.69%	26.35%	-	-	-	-	-	-	-
Branded Respiratory Proair	549M	565M	501M	-	-	-	-	-	-	-
Branded Respiratory Proair Growth	-	2.91%	-11.33%	-	-	-	-	-	-	-
Branded Womens Health Products	461M	458M	426M	-	-	-	-	-	-	-
Branded Womens Health Products Growth	-	-0.65%	-6.99%	-	-	-	-	-	-	-
Branded Respiratory Qvar	392M	462M	361M	-	-	-	-	-	-	-
Branded Respiratory Qvar Growth	-	17.86%	-21.86%	-	-	-	-	-	-	-
Branded C N S Azilect	384M	410M	170M	-	-	-	-	-	-	-
Branded C N S Azilect Growth	-	6.77%	-58.54%	-	-	-	-	-	-	-
Ninlaro1	-	-	150M	-	-	-	-	-	-	-
Ninlaro1 Growth	-	-	-	-	-	-	-	-	-	-
Branded C N S Nuvigil	373M	200M	61M	-	-	-	-	-	-	-
Branded C N S Nuvigil Growth	-	-46.38%	-69.50%	-	-	-	-	-	-	-
Branded Oncology Treanda	741M	-	-	-	-	-	-	-	-	-
Branded Oncology Treanda Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	-	-	8.45B	7.81B	7.45B	8.12B	8.03B
North America Growth	-	-	-	-	-	-	-7.55%	-4.57%	9.02%	-1.11%
Europe	-	-	-	-	-	4.76B	4.89B	4.53B	4.84B	5.1B
Europe Growth	-	-	-	-	-	-	2.71%	-7.39%	6.90%	5.50%
International Markets	-	-	-	-	-	2.15B	2.03B	1.9B	1.96B	2.46B
International Markets Growth	-	-	-	-	-	-	-5.66%	-6.35%	2.89%	25.79%
North America	-	-	-	7.84B	6.94B	-	-	-	-	-
North America Growth	-	-	-	-	-11.44%	-	-	-	-	-
Europe	-	-	-	5.15B	4.77B	-	-	-	-	-
Europe Growth	-	-	-	-	-7.43%	-	-	-	-	-
Rest Of The World	3.51B	4.84B	655M	-	-	-	-	-	-	-
Rest Of The World Growth	-	37.92%	-86.48%	-	-	-	-	-	-	-
Europe Group Two	4.89B	5.41B	308M	-	-	-	-	-	-	-
Europe Group Two Growth	-	10.61%	-94.31%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Teva Pharmaceutical Industries Limited (TEVA) reported $16.78B in revenue for fiscal year 2024. This represents a 8% decrease from $18.31B in 2011.

Teva Pharmaceutical Industries Limited (TEVA) grew revenue by 4.4% over the past year. Growth has been modest.

Yes, Teva Pharmaceutical Industries Limited (TEVA) is profitable, generating $712.0M in net income for fiscal year 2024 (-9.9% net margin).

Dividend & Returns

Teva Pharmaceutical Industries Limited (TEVA) has a return on equity (ROE) of -23.7%. Negative ROE indicates the company is unprofitable.

Teva Pharmaceutical Industries Limited (TEVA) generated $918.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.